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PAST
Anal squamous cell carcinoma (SSC) is a relatively rare
malignancy with an increasing incidence over the last
years. Chemoradiotherapy (CRT) has replaced surgery as
treatment for primary anal SCC and is currently standard of
care for primary anal SCC. Treatment with CRT leads to
preservation of the anal sphincter and a 5-year survival rate
up to 80%. Failure of CRT occurs in 20–30% of the
patients, resulting in persistent or recurrent anal SCC. The
only available treatment option to achieve durable local
control and survival for persistent or recurrent anal SCC is
salvage abdominoperineal resection (APR).1 Outcomes of
salvage APR for anal SCC were previously described in
small and heterogenic groups and with variance in treat-
ment protocols. This study evaluated oncologic outcomes
and prognostic factors after salvage APR for anal SCC over
almost 3 decades with little change in treatment protocol.
PRESENT
This study confirmed that salvage APR for either per-
sistent or recurrent anal SCC, after failed initial treatment
with CRT, can achieve long-term survival and durable
local control.2 An overall 5-year survival rate of 41.6% was
achieved, and the 5-year local recurrence rate was 44.7%.
There was no difference in survival between persistent or
recurrent anal SCC. Important prognostic factors associ-
ated with decreased survival are an increased pathological
tumour size, positive lymph nodes, and involved resection
margins. These prognostic factors have been described
previously. Achievement of clear resection margins is the
most important prognostic factor, which affects survival
and local control. This study confirms the benefit of salvage
APR for persistent or recurrent anal SCC after failure of
primary treatment with CRT. Surgical treatment of re-re-
currence after salvage APR, however, does not appear to be
useful.
FUTURE
The use of salvage APR is well established, but
achievement of a higher rate of clear resection margins
remains a challenge. Intraoperative radiation therapy could
be of value to improve overall survival and local control,
but further research is warranted.3
The biggest challenge remains systemic treatment of
unresectable or metastasized anal SCC. Current systemic
chemotherapy schemes often are based on 5-FU and Cis-
platin and show poor response and survival rates.4
However, a recent promising phase-II trial with combined
treatment of docetaxel, cisplatin, and fluorouracil for
patients with metastatic or unresectable locally recurrent
anal SCC showed a high proportion of complete responses
and long-term remissions.5 Other randomized, controlled
trials, including taxanes, targeted therapy, and
immunotherapy, are currently performed and could provide
promising treatment strategies in the near future. Further
investigation should establish the use of these therapies.
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